



**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
**宜明昂科生物醫藥技術（上海）股份有限公司**  
(A joint stock company incorporated in the People's Republic of China with limited liability)  
(於中華人民共和國註冊成立的股份有限公司)  
(Stock Code 股份代號: 1541)

20 February 2024

Dear non-registered shareholder(s),

**Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07 of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “**Corporate Communications**”), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.immuneonco.com](http://www.immuneonco.com) and the HKEXnews website at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies (the “**Website Version**”). A notice of publication of the Website Version of Corporate Communications, in both English and Chinese, will be sent by the Company to its shareholders by email or by post (only if the Company does not possess the functional email address of the shareholder) on the publication date of the Corporate Communications.

As a non-registered shareholder, if you wish to receive Corporate Communications from the Company pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your Shares are held (collectively, the “**Intermediaries**”) and provide your email address to your Intermediaries.

If the Company does not receive your functional email address from the Intermediaries, until such time that the functional email address is provided to the Intermediaries, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications; and (ii) need to proactively check the Company’s website and the HKEXnews website to keep up with the publication of Corporate Communications.

If you want to receive the Corporate Communications in printed form, please complete and return the reply form on the reverse side to the Company, Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai PRC or send an email to [ir@immuneonco.com](mailto:ir@immuneonco.com) specifying your name, address and request to receive the Corporate Communications in printed form.

Should you have any queries relating to this letter, please contact the Company at 86-021-38016387 during business hours from 9:00 a.m. to 5:30 p.m. (Hong Kong time), Mondays to Fridays, excluding public holidays in Hong Kong and Mainland China.

Yours faithfully,  
By order of the Board  
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  
Tian Wenzhi  
Chairman

各位非登記股東：

**以電子方式發布公司通訊之安排**

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則（「**上市規則**」）第 2.07 條，宜明昂科生物醫藥技術（上海）股份有限公司（「**公司**」）謹此通知 閣下，公司已採用以電子方式發布公司通訊（「**公司通訊**」）之安排，該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 [www.immuneonco.com](http://www.immuneonco.com) 和披露易網站 [www.hkexnews.hk](http://www.hkexnews.hk) 上提供，以代替印刷本（「**網站版本**」）。本公司將於公司通訊刊發日期通過電子郵件方式或郵寄方式（僅在本公司沒有獲取股東有效的電子郵箱地址時）向股東發送公司通訊網站版本的登載通知，該通知將同時提供英文和中文版本。

作為非登記股東，如有意根據《上市規則》收取公司通訊，閣下應聯絡代 閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「**中介公司**」），並向閣下的中介公司提供閣下的電子郵件地址。

如果公司沒有從中介公司收到閣下的有效電子郵件地址，直至中介公司收到閣下有效的電子郵件地址前，閣下將(i)無法收到任何有關發佈公司通訊的通知；及(ii)需要主動查看公司網站和披露易網站以留意公司通訊的發佈。

若 閣下希望收取公司通訊之印刷版，請填妥本函背頁之回條並交回公司，地址為上海浦東新區張衡路 1000 弄 15 號樓或發送電子郵件至 [ir@immuneonco.com](mailto:ir@immuneonco.com)，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。

如 閣下對本函件有任何疑問，請於辦公時間星期一至五（香港及中國大陸公眾假期除外）上午 9 時正至下午 5：30 時（香港時間）其間致電公司 86-021-38016387 查詢。

承董事會命  
宜明昂科生物醫藥技術（上海）股份有限公司  
田文志  
董事長  
謹啟

2024 年 2 月 20 日



## REPLY FORM 回條

To: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  
(The Company)  
Unit 15, 1000 Zhangheng Road  
China (Shanghai) Pilot Free Trade Zone  
Pudong New Area  
Shanghai PRC 201203

致： 宜明昂科生物醫藥技術（上海）股份有限公司  
（公司）  
中國上海浦東新區張衡路 1000 弄 15 號，201203

### REMINDER 提示

As a non-registered shareholder, if you wish to receive Corporate Communications\* pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

作為非登記股東，如有意根據《上市規則》收取公司通訊\*，閣下應聯絡代 閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算（代理人）有限公司（統稱「中介公司」），並向 閣下的中介公司提供 閣下的電子郵件地址。

### Request for Corporate Communications\* in printed form / 要求收取公司通訊\*印刷版

(Please mark "✓" in the below box if applicable) (如適用，請在以下方格內劃上「✓」號)

Name of the listed company (the "Company"): ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  
上市公司（「公司」）名稱： 宜明昂科生物醫藥技術（上海）股份有限公司

I/we would like to receive future Corporate Communications\* in printed form.  
本人/我們欲收取未來公司通訊\*的印刷版。

Name(s) of Non-registered holder(s):

非登記股東姓名：

Signature(s): (Notes 1)

簽名：(附註 1)

(Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫)

Contact number:

聯絡電話號碼：

Date:

日期：

Notes:

附註：

- This letter is addressed to Non-registered holder(s) ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications\*). 此函件乃向本公司之非登記股東（「非登記股東」指股份存放於中央結算及交收系統的人士或公司，已透過香港中央結算有限公司不時向本公司發出通知，表示欲收取公司通訊\*）發出。
- Please complete all your details clearly. 請 閣下清楚填妥所有資料。
- Any form with no box marked (✓), with no signature or otherwise incorrectly completed will be void. 如在本表格未有在方格內劃上「✓」號，或未有簽署，或在其他方面填寫不正確，則本表格將會作廢。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form. 為免存疑，在本回條上的任何額外指示，公司將不予處理。

\* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明，公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

#### PERSONAL INFORMATION COLLECTION STATEMENT

收集個人資料聲明

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). 本聲明中所指的「個人資料」與香港法例第 486 章《個人資料（私隱）條例》（「《私隱條例》」）中「個人資料」的涵義相同。
- Your Personal Data provided in this Reply Form will be used in connection with the Company's electronic dissemination of Corporate Communications. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in this Reply Form. 閣下於本回條所提供的個人資料將用於有關公司以電子方式發布公司通訊的事宜上。閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料，本公司可能無法處理 閣下在本回條上所述的指示及/或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes. 閣下可就任何所說明的用途或在法例規定的情況下，將 閣下的個人資料披露或轉移給公司的附屬公司、股份過戶處、及/或其他公司或團體，並將在適當期間保留該等個人資料作核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at [PrivacyOfficer@computershare.com.hk](mailto:PrivacyOfficer@computershare.com.hk). 閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至股份過戶處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 [PrivacyOfficer@computershare.com.hk](mailto:PrivacyOfficer@computershare.com.hk)。